There have been no open-market insider trades at Syros Pharmaceuticals, Inc. in the last 12 months.
No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
There have been no open-market insider trades at Syros Pharmaceuticals, Inc. in the last 12 months.
No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Dec 4, 2024 | Simonian Nancy A | Director | Sell | 37,070 | $0.27 | $10K | SEC |
| Nov 27, 2024 | Simonian Nancy A | Director | Sell | 134,713 | $0.27 | $36K | SEC |
| Nov 20, 2024 | Stephens Kristin | Executive Officer | Sell | 36,133 | $0.22 | $8K | SEC |
| Nov 20, 2024 | Roth David | Executive Officer | Sell | 12,099 | $0.20 | $2K | SEC |
| Nov 20, 2024 | Quirk Gerald E | Executive Officer | Sell | 46,657 | $0.22 | $10K | SEC |
| Nov 20, 2024 | Chee Conley | CEO | Sell | 134,797 | $0.20 | $27K | SEC |
| Nov 20, 2024 | Haas Jason | CFO | Sell | 137,803 | $0.21 | $29K | SEC |
| Sep 12, 2024 | Chee Conley | CEO | Buy | 50,000 | $1.51 | $76K | SEC |
| Sep 12, 2024 | Chee Conley | CEO | Buy | 50,000 | $1.71 | $86K | SEC |
| Sep 12, 2024 | Haas Jason | CFO | Buy | 19,293 | $1.58 | $30K | SEC |
| Sep 12, 2024 | Haas Jason | CFO | Buy | 45,344 | $1.68 | $76K | SEC |
| Sep 12, 2024 | Haas Jason | CFO | Buy | 35,363 | $1.55 | $55K | SEC |
| Jul 2, 2024 | Young Richard A | Director | Sell | 34,837 | $5.12 | $178K | SEC |
| Apr 5, 2024 | Roth David | Executive Officer | Sell | 10,451 | $4.95 | $52K | SEC |
| Apr 2, 2024 | Roth David | Executive Officer | Sell | 150 | $4.98 | $747 | SEC |
There were no open-market insider trades in SYRS in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
No congressional trades in SYRS were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).